Provision of continuous subcutaneous insulin infusion to type 1 diabetes 'frequent flyers'.
Lisa A AmatoRomana KaloloWilliam YuDavid SimmonsPublished in: Internal medicine journal (2023)
A few people with type 1 diabetes undergo multiple hospital admissions for acute glycaemic events. We report on a series of five such 'frequent flyers' who were provided with continuous subcutaneous insulin infusion (CSII) therapy. Mean HbA1c decreased from 9.7 ± 2.5% (83 ± 27 mmol/mol) to 7.9 ± 0.4% (63 ± 4.7 mmol/mol) after 2-4 months. Frequency of admissions for acute glycaemic events reduced in three but increased in two patients within 6 months. Total insulin dose and body mass index decreased in some patients and satisfaction was anecdotally higher. Some, but not all, 'frequent flyers' benefited from a trial of CSII.
Keyphrases
- type diabetes
- end stage renal disease
- body mass index
- chronic kidney disease
- ejection fraction
- glycemic control
- newly diagnosed
- peritoneal dialysis
- low dose
- cardiovascular disease
- clinical trial
- prognostic factors
- liver failure
- stem cells
- study protocol
- metabolic syndrome
- physical activity
- drug induced
- patient reported outcomes
- adipose tissue
- skeletal muscle
- hepatitis b virus
- patient reported
- weight gain
- phase iii